Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Objectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib.Methods Data were from two phase III studies; patients received...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2060924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832088392448344064 |
|---|---|
| author | Peter C. Taylor Andrew G. Bushmakin Joseph C. Cappelleri Pamela Young Rebecca Germino Joseph F. Merola Gil Yosipovitch |
| author_facet | Peter C. Taylor Andrew G. Bushmakin Joseph C. Cappelleri Pamela Young Rebecca Germino Joseph F. Merola Gil Yosipovitch |
| author_sort | Peter C. Taylor |
| collection | DOAJ |
| description | Objectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib.Methods Data were from two phase III studies; patients received tofacitinib 5 or 10 mg twice daily (BID), adalimumab 40 mg every other week, or placebo advancing to tofacitinib 5 or 10 mg BID at Month 3. Repeated measures longitudinal models assessed relationships between dermatologic assessments (predictors) Itch Severity Item (ISI), Physician’s Global Assessment of Psoriasis (PGA-PsO), and Patient’s Global Joint and Skin Assessment-Visual Analog Scale-Psoriasis question (PGJS-VAS-PsO), and QoL measures (outcomes) Dermatology Life Quality Index (DLQI) and Short Form-36 Health Survey Version 2 (SF-36v2). Models included one predictor and one outcome.Results Direct, approximately linear relationships existed between predictors and outcomes. ISI/PGA-PsO/PGJS-VAS-PsO improvements from baseline of ≥3/≥2/≥40-mm VAS corresponded with clinically meaningful DLQI improvements; improvements from baseline of ≥4/≥3/≥40-mm VAS generally corresponded with clinically meaningful improvements across component scores and all SF-36v2 domains.Conclusions Substantial links exist between dermatologic symptoms and QoL in patients with PsA, potentially informing patient-centered care and research. Rheumatologists should be aware of dermatologic manifestations and QoL impacts in patients with PsA.ClinicalTrials.gov NCT01877668; NCT01882439 |
| format | Article |
| id | doaj-art-36331613aa964370bddc4222d95f8cda |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-36331613aa964370bddc4222d95f8cda2025-02-05T19:02:55ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-07-013352614262010.1080/09546634.2022.2060924Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studiesPeter C. Taylor0Andrew G. Bushmakin1Joseph C. Cappelleri2Pamela Young3Rebecca Germino4Joseph F. Merola5Gil Yosipovitch6Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UKPfizer Inc, Groton, CT, USAPfizer Inc, Groton, CT, USAPfizer Inc, Collegeville, PA, USAPfizer Inc, New York, NY, USAHarvard Medical School, Brigham and Women’s Hospital, Boston, MA, USADepartment of Dermatology and Itch Center, University of Miami Miller School, Miami, FL, USAObjectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib.Methods Data were from two phase III studies; patients received tofacitinib 5 or 10 mg twice daily (BID), adalimumab 40 mg every other week, or placebo advancing to tofacitinib 5 or 10 mg BID at Month 3. Repeated measures longitudinal models assessed relationships between dermatologic assessments (predictors) Itch Severity Item (ISI), Physician’s Global Assessment of Psoriasis (PGA-PsO), and Patient’s Global Joint and Skin Assessment-Visual Analog Scale-Psoriasis question (PGJS-VAS-PsO), and QoL measures (outcomes) Dermatology Life Quality Index (DLQI) and Short Form-36 Health Survey Version 2 (SF-36v2). Models included one predictor and one outcome.Results Direct, approximately linear relationships existed between predictors and outcomes. ISI/PGA-PsO/PGJS-VAS-PsO improvements from baseline of ≥3/≥2/≥40-mm VAS corresponded with clinically meaningful DLQI improvements; improvements from baseline of ≥4/≥3/≥40-mm VAS generally corresponded with clinically meaningful improvements across component scores and all SF-36v2 domains.Conclusions Substantial links exist between dermatologic symptoms and QoL in patients with PsA, potentially informing patient-centered care and research. Rheumatologists should be aware of dermatologic manifestations and QoL impacts in patients with PsA.ClinicalTrials.gov NCT01877668; NCT01882439https://www.tandfonline.com/doi/10.1080/09546634.2022.2060924Psoriatic arthritistofacitinibdermatologicquality of life |
| spellingShingle | Peter C. Taylor Andrew G. Bushmakin Joseph C. Cappelleri Pamela Young Rebecca Germino Joseph F. Merola Gil Yosipovitch Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies Journal of Dermatological Treatment Psoriatic arthritis tofacitinib dermatologic quality of life |
| title | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies |
| title_full | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies |
| title_fullStr | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies |
| title_full_unstemmed | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies |
| title_short | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies |
| title_sort | relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis analysis of two tofacitinib phase iii studies |
| topic | Psoriatic arthritis tofacitinib dermatologic quality of life |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2022.2060924 |
| work_keys_str_mv | AT peterctaylor relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT andrewgbushmakin relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT josephccappelleri relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT pamelayoung relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT rebeccagermino relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT josephfmerola relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies AT gilyosipovitch relationshipsofdermatologicsymptomsandqualityoflifeinpatientswithpsoriaticarthritisanalysisoftwotofacitinibphaseiiistudies |